Genital Neoplasms, Female Clinical Trial
Official title:
Characterization of the Intestinal and Vaginal Microbiota in Long-term Survivors of Gynecological Cancer and Its Association With Quality of Life and Sexual Health
The study proposes the characterization of the intestinal and vaginal microbiota in long-term radiated cervical and endometrial cancer survivors to study the association with long-term radiotherapy side effects.
The human epithelial surface is colonized by a community of microorganisms, the microbiota, which disruption (dysbiosis) can impact a variety of functions, leading to inflammation, altered immunity and numerous diseases, including cancer. Pelvic cancers are among the most frequently diagnosed cancers worldwide, and pelvic radiotherapy is often an essential part of multimodal therapeutic approaches but can lead to a wide range of complications for which there is currently no treatment. The gut microbiota is altered by radiotherapy, and a relationship between gut microbiota composition, health status, and pelvic radiotherapy has been suggested. In recent years, there has been growing evidence that radiotherapy also alters the vaginal microbiota. The study proposes the characterization of the intestinal and vaginal microbiota in long-term radiated cervical and endometrial cancer survivors to study its association with long-term radiotherapy side effects. For this purpose, a descriptive cross-sectional study will be carried out in patients affected by cervical or endometrial cancer, in early stages, with good vital prognosis who have received radiotherapy, using healthy postmenopausal women as a control group. If the microbiota is indeed associated with the side effects of radiotherapy, this would open the possibility of identifying predictive markers, using machine learning analysis of the patients' quality of life, and would help in the search for future therapies based on the restoration of the vaginal and intestinal microbiota. Through network analysis, it would be possible to find out which factors related to patients' diet and lifestyle could be related to dysbiosis and radiotherapy-induced adverse outcomes and poor quality of life. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05051696 -
Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies
|
Phase 2 | |
Completed |
NCT00377520 -
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT04566952 -
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02182245 -
Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies
|
Phase 1 | |
Completed |
NCT00191646 -
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
|
Phase 3 | |
Completed |
NCT00121030 -
Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy
|
Phase 2 | |
Recruiting |
NCT04556071 -
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT04679675 -
Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial
|
N/A | |
Terminated |
NCT00332280 -
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04807166 -
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02966327 -
Effect of Early Compression and Exercise on Lymphedema Incidence in Patients With Gynecological Cancer
|
N/A | |
Completed |
NCT01654458 -
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
|
N/A | |
Completed |
NCT02609880 -
Cognitive Behavioral Effects on Sleep, Pain, and Cytokines in Gynecologic Cancer
|
N/A | |
Completed |
NCT00191607 -
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
|
Phase 3 | |
Terminated |
NCT02499952 -
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
|
Phase 2 | |
Terminated |
NCT01032447 -
Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program
|
N/A | |
Recruiting |
NCT02781155 -
Limiting Chemotherapy Side Effects by Using Moxa
|
Phase 1/Phase 2 | |
Recruiting |
NCT00391664 -
Questionnaire Study for Gynecological Cancer Survivors
|
N/A | |
Completed |
NCT00190983 -
A Trial for Patients With Advanced/Recurrent Cervical Cancer
|
Phase 2 | |
Completed |
NCT00523432 -
A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
|
Phase 1 |